| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Laboratory Medicine and Pathology (C.M.P., D.J.O’K., R.J.S., S.K.G.G.) and Medicine (J.C.M., S.K.G.G.), Mayo Clinic, Rochester, Minnesota 55905
Address all correspondence and requests for reprints to: Dr. Stefan K. G. Grebe, Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 1st Street SW, Rochester, Minnesota 55905. E-mail: grebs{at}mayo.edu.
Serum thyroglobulin (Tg) measurement is a major means of detecting thyroid cancer recurrence. Unlike anti-Tg autoantibody interferences, heterophile antibody (HAB) immunoassay interferences are not well recognized by laboratorians or clinicians as a Tg assay problem. When HAB interferences occur, they usually result in false positive test results. With the current trend to treat some thyroid cancer patients with radioiodine on the basis of an elevated serum Tg result alone, this has the potential to result in unwarranted therapy.
We evaluated the prevalence of HAB interference in a commonly used automated immunoassay in 1106 consecutive specimens with Tg values greater than 1 ng/ml. All Tg measurements were repeated after sample incubation in heterophile-blocking tubes (HBT). Results, which showed a more than 3 SD percentage difference from the original result, were considered to suffer from HAB interference. All possible interferences were confirmed by dilution testing.
After HBT treatment, Tg levels dropped to less than 1 ng/ml in 32 specimens (P < 0.0000001), 20 of which fell to less than 0.1 ng/ml (P < 0.00002). Of these 20, 17 were anti-Tg autoantibody negative, and all 32 showed a fall of greater than 3 SD percentage (>56.91%) compared with the original result. There were also two samples that showed a significant increase of greater than 56.91% after HBT treatment.
HAB interference is relatively prevalent (1.5–3%) in a commonly used automated Tg assay and can lead to clinically significant artifacts. It is currently unknown, but possible, that other immunometric Tg assays suffer from similar problems. Unless a Tg assay is confirmed to be free of HAB interference or uses additional blocking steps, as ours now does, HAB interference should be suspected if Tg results do not fit the clinical picture.
This work was supported by the Mayo Clinic Department of Laboratory Medicine and Pathology and the Mayo Foundation.
Abbreviations: CV, Coefficient(s) of variation; HAB, heterophile antibody; HAMA, human antimouse antibodies; HBT, heterophile-blocking tubes; Ig, immunoglobulin; Tg, thyroglobulin.
This article has been cited by other articles:
 |
|
 |
|
  L. Giovanella and A. Ghelfo Undetectable Serum Thyroglobulin Due to Negative Interference of Heterophile Antibodies in Relapsing Thyroid Carcinoma Clin. Chem., October 1, 2007; 53(10): 1871 - 1872. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Schlumberger, A. Hitzel, M. E. Toubert, C. Corone, F. Troalen, M. H. Schlageter, F. Claustrat, S. Koscielny, D. Taieb, M. Toubeau, et al. Comparison of Seven Serum Thyroglobulin Assays in the Follow-Up of Papillary and Follicular Thyroid Cancer Patients J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2487 - 2495. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C.M. Persoon, J. M.W. Van Den Ouweland, J. Wilde, I. P. Kema, B. H.R. Wolffenbuttel, and T. P. Links Clinical utility of an automated immunochemiluminometric thyroglobulin assay in differentiated thyroid carcinoma. Clin. Chem., April 1, 2006; 52(4): 686 - 691. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Stockigt Ambiguous Thyroglobulin Assay Results in the Follow-Up of Differentiated Thyroid Carcinoma J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5904 - 5905. [Full Text] [PDF]
|
|
|
|
|
|
C. A. Spencer, L. M. Bergoglio, M. Kazarosyan, S. Fatemi, and J. S. LoPresti Clinical Impact of Thyroglobulin (Tg) and Tg Autoantibody Method Differences on the Management of Patients with Differentiated Thyroid Carcinomas J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5566 - 5575. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. L. Mazzaferri Empirically Treating High Serum Thyroglobulin Levels J. Nucl. Med., July 1, 2005; 46(7): 1079 - 1088. [Full Text] [PDF]
|
|
|
|
|
|
M. J. Ellis and J. H. Livesey Techniques for Identifying Heterophile Antibody Interference Are Assay Specific: Study of Seven Analytes on Two Automated Immunoassay Analyzers Clin. Chem., March 1, 2005; 51(3): 639 - 641. [Full Text] [PDF]
|
|
|
|
|
|
C. M. Preissner, L. A. Dodge, D. J. O'Kane, R. J. Singh, and S. K.G. Grebe Prevalence of Heterophilic Antibody Interference in Eight Automated Tumor Marker Immunoassays Clin. Chem., January 1, 2005; 51(1): 208 - 210. [Full Text] [PDF]
|
|
|
|
|
|
C. A. Spencer Challenges of Serum Thyroglobulin (Tg) Measurement in the Presence of Tg Autoantibodies J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3702 - 3704. [Full Text] [PDF]
|
|
|
|
|
|
G. Ward and P. E. Hickman Phantoms in the Assay Tube J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 433 - 433. [Full Text] [PDF]
|
|
|
|
|
|
S. K. G. Grebe Authors' Response: Phantoms in the Assay Tube J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 433 - 433. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
